课题基金 / 基金详情

The Role of Desoxysphingoid Bases in HSAN1

The Role of Desoxysphingoid Bases in HSAN1
脱氧鞘氨醇碱基在 HSAN1 中的作用
批准号:
8627660
负责人:
FLORIAN S EICHLER
金额:
$40.79万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-03-15 至 2016-02-28

项目摘要

项目成果

FLORIAN S EICHLER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The proposed interdisciplinary study addresses the debilitating disorder of hereditary sensory and autonomic neuropathy type 1 (HSAN1) and is based on the insight that mutant serine palmitoyltransferase (SPT) activity leads to production of two potentially neurotoxic sphingolipids. We were the first to identify the accumulation of these two atypical desoxysphingoid bases (DSB) in both mutant HSAN1 transgenic mice and HSAN1 patients. The studies bring together expertise in biochemistry (Uniformed Services University, USUHS) and neuroscience and neurogenetics (Massachusetts General Hospital). The project will (1) investigate mutant SPT isozymes in yeast and mammalian cells, (2) perform neurotoxicity studies of the atypical sphingolipids in mice, and (3) assess amino acid supplementation in mutant HSAN1 transgenic mice. The central premise underlying these investigations is that amino acid substrate selectivity alters desoxysphingoid bases and disease severity in HSAN1. Closely related is the premise that one can use behavioral testing and neuropathological examinations to assess the biochemical impact upon the clinicopathological phenotype. We will begin by expressing mutant SPT heterotrimers containing the known HSAN1 mutations in yeast and in mammalian cells (Aim 1). The Km and Vmax of each mutant enzyme for serine, alanine and glycine will be determined using these labeled amino acids. These experiments will allow us to determine whether the mutations differ in their abilities to condense the alternative substrates (alanine and glycine) and inform our studies in rodents. Neurotoxicity studies (Aim 2) will determine the role of DSB in peripheral neurodegeneration of HSAN1 in vivo. Lastly dietary supplementation of serine versus alanine and glycine in mutant HSAN1 transgenic mice will allow us to test behavior and neuropathology in vivo (Aim 3) and prepare for clinical studies in humans. These ex vivo and in vivo studies will give us insight about the synthesis, degradation and neurotoxicity of DSB in HSAN1. The experiments will not only elucidate a new and fundamental insight into neurometabolism but also lead to a potential new treatment for a neurogenetic disorder.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)
  • 批准号:
    10704432
  • 项目类别:
  • 资助金额:
    $13.77万
  • 财政年份:
    2019
  • 负责人:
    FLORIAN S EICHLER
  • 依托单位:
Myelin Disorders Biorepository Project (MDBP) at the Biospecimen Exchange for Neurological Disorders (BioSEND)
  • 批准号:
    10850332
  • 项目类别:
  • 资助金额:
    $14.34万
  • 财政年份:
    2019
  • 负责人:
    FLORIAN S EICHLER
  • 依托单位:
The Global Leukodystrophy Initiative Clinical Trials Network (GLIA-CTN)
  • 批准号:
    9804283
  • 项目类别:
  • 资助金额:
    $158.29万
  • 财政年份:
    2019
  • 负责人:
    FLORIAN S EICHLER
  • 依托单位:
海外基金